10 months ago
SPOT
AnalystsJonathan WollebenJonathan Wolleben's Stock Forecasts
AnalystsJonathan Wolleben
Analyst Ranking
Top 6%
#279 out of 5001 analysts
Average Return
+11.12%
Win Rate
50%108 out of 218
Risk vs Reward
Poor
Good
Jonathan Wolleben's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Madrigal Pharmaceuticals IncMDGL | +365.01% | $64.44 | $299.65 | 2022-05-10 - 2023-05-09 | Buy |
Sagimet Biosciences IncSGMT | +214.13% | $2.76 | $8.67 | 2024-08-15 - 2025-08-14 | Buy |
Pharvaris NvPHVS | +206.28% | $8.12 | $24.87 | 2023-02-27 - 2024-02-26 | Buy |
Pharvaris NvPHVS | +198.29% | $8.75 | $26.10 | 2023-01-11 - 2024-01-10 | Buy |
Pharvaris NvPHVS | +194.90% | $8.62 | $25.42 | 2022-12-09 - 2023-12-08 | Buy |
Jonathan Wolleben Analyst Color
Get additional color on Jonathan Wolleben's coverage of popular stocks
Jonathan Wolleben's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals IncMDGL | 11 | Buy | $485.00 | +10.77% | Maintains | 11 days ago |
Larimar Therapeutics IncLRMR | 13 | Buy | $18.00 | +397.24% | Reiterates | 12 days ago |
Pharvaris NvPHVS | 12 | Buy | $52.00 | +140.18% | Maintains | 18 days ago |
Astria Therapeutics IncATXS | 3 | Buy | $26.00 | +320.71% | Maintains | 18 days ago |
Quince Therapeutics IncQNCX | 2 | Buy | $8.00 | +400.00% | Maintains | 19 days ago |
Crinetics Pharmaceuticals IncCRNX | 15 | Buy | $86.00 | +177.51% | Maintains | 20 days ago |
Protagonist Therapeutics IncPTGX | 12 | Buy | $69.00 | +16.85% | Maintains | 24 days ago |
Mirum Pharmaceuticals IncMIRM | 11 | Buy | $81.00 | +9.65% | Maintains | 24 days ago |
Structure Therapeutics IncGPCR | 10 | Buy | $87.00 | +350.78% | Maintains | 24 days ago |
Rhythm Pharmaceuticals IncRYTM | 4 | Buy | $135.00 | +30.88% | Maintains | 25 days ago |
Altimmune IncALT | 12 | Buy | $15.00 | +291.64% | Maintains | 2 months ago |
Kalvista Pharmaceuticals IncKALV | 4 | Buy | $27.00 | +100.59% | Maintains | 2 months ago |
Proqr Therapeutics NvPRQR | 6 | Buy | $8.00 | +255.56% | Reiterates | 2 months ago |
Dbv Technologies SaDBVT | 15 | Buy | $21.00 | +117.62% | Reiterates | 2 months ago |
Skye Bioscience IncSKYE | 3 | Buy | $15.00 | +328.57% | Reiterates | 2 months ago |
Aura Biosciences IncAURA | 9 | Buy | $19.00 | +203.51% | Reiterates | 3 months ago |
Clearside Biomedical IncCLSD | 10 | Buy | $5.00 | +1,262.40% | Reiterates | 3 months ago |
Mbx Biosciences IncMBX | 1 | Buy | $38.00 | +151.82% | Initiates Coverage On | 5 months ago |
Ocular Therapeutix IncOCUL | 15 | Buy | $19.00 | +55.61% | Maintains | 6 months ago |
Biocryst Pharmaceuticals IncBCRX | 8 | Buy | $18.00 | +116.61% | Reiterates | 6 months ago |
Savara IncSVRA | 8 | Buy | $9.00 | +174.39% | Reiterates | 8 months ago |
Hilton Grand Vacations IncHGV | 1 | Buy | $50.00 | +5.22% | Maintains | 8 months ago |
Costar Group IncCSGP | 1 | Buy | $90.00 | +0.57% | Reiterates | 8 months ago |
Spruce Biosciences IncSPRB | 7 | Hold | $3.00 | +3,514.46% | Downgrades | 9 months ago |
Spotify Technology SaSPOT | 1 | Buy | $485.00 | -28.87% | Downgrades | 10 months ago |
Allakos IncALLK | 6 | Buy | $3.00 | +811.85% | Reiterates | a year ago |
Sagimet Biosciences IncSGMT | 8 | Buy | $32.00 | N/A | Maintains | a year ago |
Rallybio CorpRLYB | 11 | Buy | $8.00 | N/A | Reiterates | a year ago |
Warner Music Group CorpWMG | 1 | Buy | $24.00 | N/A | Maintains | 2 years ago |
Strongbridge Biopharma PLCSBBP | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.